VIA THERAPEUTICS, LLC

Austin, TX · Medtech · Private

Topical drug delivery formulations for cutaneous squamous cell carcinoma targeting the skin epidermis and dermis

Grants
$2.9M
8 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
$5.4M
3 awards · Health and Human S
#119 of 4531 in medtech
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Health and Human Services · Inhaled Delivery Of Clofazimine - A High Efficiency, Flow Independent, Targeted, Low Cost Dpi$3,599,145
Federal grantDepartment of Health and Human Services · Phase I · Preclinical evaluation of co-delivery of TNF-alpha siRNA and a glucocorticoid for rheumatoid arthritis$225,000
Federal grantDepartment of Health and Human Services · Phase I · Enabling the repurposing of niclosamide for castrate-resistant prostate cancer using a novel formulation technology platform$263,895
Federal grantDepartment of Health and Human Services · Phase I · Development of synergistic clofazimine-amikacin inhalable powders for the treatment of pulmonary Mycobacterium abscessus infections$256,350
Federal grantDepartment of Health and Human Services · Phase I · Discovery of epidermal/dermal targeting formulations for cutaneous squamous cell carcinoma$251,917
Federal contractDepartment of Health and Human Services · Development Of Low-cost, Shelf-stable, Patient- Adaptable Clofazimine Mini-tablets For Treatment Of Tuberculosis In Pediatrics$299,995
Federal contractDepartment of Health and Human Services · SBIR Phase II Award To Via Therapeutics$1,468,122
Federal grantDepartment of Health and Human Services · Phase I · Inhalable dry powders of mycobacteriophages for tuberculosis therapy$300,000
Federal grantDepartment of Health and Human Services · Phase II · Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza$1,000,000
Federal grantDepartment of Health and Human Services · Phase I · Microneedle-based mRNA Flu Vaccine for Transcutaneous Immunization$314,363
Federal grantDepartment of Health and Human Services · Phase I · Combined Amikacin and Azithromycin in an Inhaled Formulation for the Treatment of NTM$314,363
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
116410 MEDICAL, INC.$5.5M$29M
117LAMBDAVISION INCORPORATED$5.4M—
118MOTION CONTROL, INC$5.4M—
119VIA THERAPEUTICS, LLC$5.4M—
120KERICURE INC.$5.3M$310K
121PERFUSION MEDICAL LLC$5.2M—
122Gate Scientific, Inc.$5.1M—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Clofazimine Mini-Tablets for Treatment of Tuberculosis in Pediatricsapplication
  • Clofazimine Mini-tablets For Treatment Of Tuberculosis In Pediatricsapplication
  • Low-Cost, Shelf-Stable, Patient-Adaptable Clofazimine Mini-Tablets for Treatment of Tuberculosis in Pediatricsapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.